According to filings with the U.S. Securities and Exchange Commission, Instylla is raising $30,034,997.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Amar Sawhney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Instylla
Instylla is focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis. Caution: Investigational Device. Limited by Federal (or US) law to Investigational use only. Not available for sale. Instylla is a privately held company based in Bedford, MA, focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis. The company’s first product, Embrace Hydrogel Embolic System, is designed for controlled, complete, and persistent embolization in these clinical conditions. Instylla was founded in 2017 by Incept LLC and is funded by several leading venture capital groups. Restoring life, hope, and joy to the world’s sickest patients by materializing novel embolization solutions to improve outcomes.

To learn more about Instylla, visit http://www.instylla.com/

Contact:
Amar Sawhney, Chief Executive Officer
617-510-3859
https://www.linkedin.com/in/amar-sawhney-a4b143/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.